ACLX
Price
$67.16
Change
+$0.82 (+1.24%)
Updated
Jul 3 closing price
Capitalization
3.7B
43 days until earnings call
RNA
Price
$29.17
Change
-$0.19 (-0.65%)
Updated
Jul 3 closing price
Capitalization
3.52B
37 days until earnings call
Interact to see
Advertisement

ACLX vs RNA

Header iconACLX vs RNA Comparison
Open Charts ACLX vs RNABanner chart's image
Arcellx
Price$67.16
Change+$0.82 (+1.24%)
Volume$166.18K
Capitalization3.7B
Avidity Biosciences
Price$29.17
Change-$0.19 (-0.65%)
Volume$553.95K
Capitalization3.52B
ACLX vs RNA Comparison Chart in %
Loading...
ACLX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACLX vs. RNA commentary
Jul 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACLX is a Buy and RNA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 06, 2025
Stock price -- (ACLX: $67.16 vs. RNA: $29.17)
Brand notoriety: ACLX and RNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACLX: 22% vs. RNA: 41%
Market capitalization -- ACLX: $3.7B vs. RNA: $3.52B
ACLX [@Biotechnology] is valued at $3.7B. RNA’s [@Biotechnology] market capitalization is $3.52B. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACLX’s FA Score shows that 0 FA rating(s) are green whileRNA’s FA Score has 0 green FA rating(s).

  • ACLX’s FA Score: 0 green, 5 red.
  • RNA’s FA Score: 0 green, 5 red.
According to our system of comparison, ACLX is a better buy in the long-term than RNA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACLX’s TA Score shows that 5 TA indicator(s) are bullish while RNA’s TA Score has 3 bullish TA indicator(s).

  • ACLX’s TA Score: 5 bullish, 3 bearish.
  • RNA’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, ACLX is a better buy in the short-term than RNA.

Price Growth

ACLX (@Biotechnology) experienced а +3.69% price change this week, while RNA (@Biotechnology) price change was -2.21% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.30%. For the same industry, the average monthly price growth was +17.40%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

ACLX is expected to report earnings on Aug 18, 2025.

RNA is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+6.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACLX($3.7B) has a higher market cap than RNA($3.52B). RNA YTD gains are higher at: 0.309 vs. ACLX (-12.427). ACLX has higher annual earnings (EBITDA): -153.96M vs. RNA (-430.35M). RNA has more cash in the bank: 1.38B vs. ACLX (543M). RNA has less debt than ACLX: RNA (5.97M) vs ACLX (53.2M). ACLX has higher revenues than RNA: ACLX (76.8M) vs RNA (8.93M).
ACLXRNAACLX / RNA
Capitalization3.7B3.52B105%
EBITDA-153.96M-430.35M36%
Gain YTD-12.4270.309-4,015%
P/E RatioN/AN/A-
Revenue76.8M8.93M860%
Total Cash543M1.38B39%
Total Debt53.2M5.97M891%
TECHNICAL ANALYSIS
Technical Analysis
ACLXRNA
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
79%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
74%
Bullish Trend 3 days ago
84%
Momentum
ODDS (%)
Bullish Trend 3 days ago
89%
Bearish Trend 3 days ago
89%
MACD
ODDS (%)
Bullish Trend 3 days ago
87%
Bearish Trend 3 days ago
79%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
89%
Bearish Trend 3 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
88%
Bearish Trend 3 days ago
86%
Advances
ODDS (%)
Bullish Trend 3 days ago
87%
Bullish Trend 4 days ago
85%
Declines
ODDS (%)
Bearish Trend 19 days ago
79%
Bearish Trend 6 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
77%
Aroon
ODDS (%)
N/A
Bullish Trend 3 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
ACLX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GGORX10.880.16
+1.49%
Goldman Sachs Mid Cap Growth R
FKAIX51.760.48
+0.94%
Federated Hermes Kaufmann Small Cap IS
SUPCX19.370.15
+0.78%
DWS Equity Sector Strategy Fund Class C
PEYAX37.540.22
+0.59%
Putnam Large Cap Value A
ALCEX14.860.08
+0.54%
Avantis U.S. Large Cap Value G

ACLX and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACLX has been loosely correlated with CGON. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if ACLX jumps, then CGON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACLX
1D Price
Change %
ACLX100%
+1.24%
CGON - ACLX
56%
Loosely correlated
+0.82%
RNA - ACLX
56%
Loosely correlated
-0.65%
KRYS - ACLX
54%
Loosely correlated
+1.22%
DNLI - ACLX
54%
Loosely correlated
-1.41%
BEAM - ACLX
53%
Loosely correlated
+0.65%
More

RNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, RNA has been loosely correlated with ACLX. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if RNA jumps, then ACLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RNA
1D Price
Change %
RNA100%
-0.65%
ACLX - RNA
56%
Loosely correlated
+1.24%
DYN - RNA
56%
Loosely correlated
-2.01%
NRIX - RNA
55%
Loosely correlated
+2.33%
OCUL - RNA
51%
Loosely correlated
+1.69%
STOK - RNA
51%
Loosely correlated
-0.61%
More